Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Akcea Therapeutics (AKCA) Stock Price
Media coverage about Akcea Therapeutics (NASDAQ:AKCA) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Akcea Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.05852819015 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
AKCA has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cowen restated a “buy” rating on shares of Akcea Therapeutics in a research note on Tuesday, October 31st. Finally, Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $24.00.
Shares of Akcea Therapeutics (NASDAQ:AKCA) opened at $18.83 on Wednesday. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.23. The firm has a market cap of $1,280.00 and a PE ratio of -4.78.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.